Hyperthyroidism Pharmacotherapy

Define the treatment target

Possible causes include Graves disease, nodular thyroid disease, medication-related disease, and thyroiditis. Symptom intensity, free hormone levels, clinical condition, and etiology inform whether the plan needs thionamide therapy, symptom control, definitive treatment, or evaluation for another cause. Low TSH alone should not trigger an automatic methimazole prescription.

Etiology determines whether synthesis blockade works

Thyrotoxicosis describes exposure to excess thyroid hormone; hyperthyroidism specifically describes increased hormone synthesis. Graves disease and autonomous toxic nodules generally involve excess production and may benefit from a thionamide or definitive therapy. Destructive thyroiditis releases preformed hormone, so blocking synthesis is usually ineffective; management emphasizes symptom control and, when appropriate, anti-inflammatory therapy. The distinction requires history, examination, thyroid testing, antibody or imaging evaluation as appropriate, and medication review (Katz, 2026).

Assess for clinically significant tachycardia, atrial fibrillation, volume loss, weakness, and coronary risk. Symptom severity influences urgency independently of a laboratory value. A low TSH by itself does not justify prescribing methimazole before the cause is established.

Three different therapeutic problems

For Graves disease or toxic nodular disease, excessive hormone synthesis may make synthesis-inhibiting treatment relevant. In destructive thyroiditis, circulating hormone may rise because stored hormone is released; a thionamide may not address that mechanism. In either situation, tachycardia and tremor may need separate symptom-directed therapy. A low TSH alone cannot distinguish these situations, so the etiology must be clarified before prescribing.

Mild or subclinical hyperthyroidism: weigh risk before treating

Low TSH with normal free thyroid hormone values may represent subclinical hyperthyroidism. Verify the pattern and cause before prescribing a synthesis inhibitor. Concern rises when TSH is fully suppressed, particularly in older adults or those with atrial fibrillation, osteoporosis, heart failure, or postmenopausal bone risk. For patients without major risk factors or fully suppressed TSH, clinical observation with repeat thyroid studies may be appropriate; the pharmacotherapy reference describes reassessment at approximately six-month intervals in selected patients (Katz, 2026).

Thionamides: methimazole and propylthiouracil

Prescribing and follow-up must account for free hormone trends

Drug	Textbook example initiation	Early assessment and major distinction
Methimazole	Often 10–20 mg orally daily; broader 5–40 mg/day range depends on initial free T4	Reassess free T4/T3 in about 4–6 weeks; usually preferred outside selected pregnancy/emergency contexts.
Propylthiouracil	Often 50–150 mg orally three times daily	Additional T4-to-T3 inhibition but greater hepatic-toxicity concern; usually reserved for particular indications.

These starting ranges describe common treatment approaches; dose selection must still reflect free hormone elevation, pregnancy, hepatic risk, and the cause of thyrotoxicosis. Suppressed TSH can persist during early recovery and should not be the sole reason to increase a thionamide dose while free hormone levels are improving. Review CBC and hepatic risk before treatment; a patient who develops fever or sore throat needs urgent evaluation for agranulocytosis, while jaundice, dark urine, or severe abdominal symptoms require prompt hepatic evaluation (Katz, 2026, Chapter 45).

Agent	Pharmacologic effect	Selection and safety questions
Methimazole	Inhibits synthesis of new thyroid hormone	Confirm indication, pregnancy context, adverse-effect risk, and dose monitoring.
Propylthiouracil (PTU)	Inhibits synthesis of new thyroid hormone	Use is context-dependent; hepatic toxicity and pregnancy considerations require careful assessment.

Both medicines can cause serious adverse reactions, particularly agranulocytosis and hepatic injury. Review prior reactions, concurrent disease, interacting drugs, pregnancy potential, and the ability to attend laboratory follow-up. Baseline thyroid studies and consideration of CBC and hepatic assessment support treatment planning; subsequent surveillance should follow the selected agent and clinical course.

Doses, biochemical response, and duration

Methimazole is usually preferred for nonpregnant adults with Graves disease because it permits simpler dosing and generally has a more favorable hepatic safety profile than PTU. Illustrative initial treatment ranges include methimazole 10–20 mg/day (with a broader 5–40 mg/day range by severity) and PTU 50–150 mg three times daily; these must not be applied without considering pregnancy, hepatic risk, clinical severity, and the cause of thyrotoxicosis. Obtain appropriate baseline laboratory assessment, counsel patients to stop the thionamide and obtain urgent evaluation for fever or sore throat (possible agranulocytosis) or jaundice/dark urine (possible hepatic injury), and monitor free T4 and often T3 in the early weeks because TSH suppression can persist after hormones improve (Katz, 2026).

Recheck FT4 and often T3 about every 4–6 weeks during initial treatment and titration; TSH can remain suppressed despite falling hormone levels and should not drive early dose escalation by itself. Once euthyroidism is achieved, a lower methimazole maintenance dose (often 5–10 mg/day in selected patients) may be possible. Overtreatment can induce hypothyroidism.

Graves disease treatment commonly continues about 12–24 months before reassessing the prospects for remission and relapse. TSH receptor antibody status can inform discussions but does not guarantee a sustained remission. Relapse is especially important to monitor in the first 3–6 months after stopping therapy, although later recurrence is possible. Recurrence may prompt consideration of further antithyroid therapy, radioactive iodine, or surgery, depending on the patient’s preferences, ophthalmopathy, goiter, contraindications, and access. If antithyroid therapy is discontinued, specify who will monitor for recurrence and reassess symptoms and thyroid tests, particularly during the first three to six months when relapse is common. TSH receptor antibody status contributes to risk assessment but is not sufficient to guarantee remission (Katz, 2026).

What thionamides accomplish

Methimazole and PTU inhibit synthesis of new thyroid hormone; effects depend on clearance of preexisting circulating hormone. Free T4 and T3 therefore help establish early response before TSH recovers. Treatment duration and relapse risk require follow-up after biochemical control, not an automatic stop when symptoms improve (Katz, 2026).

Baseline questions

Before treatment, confirm the patient’s thyroid studies, pregnancy situation, hepatic concerns, history of drug reactions, current medications, and ability to follow safety instructions. Baseline CBC and liver assessment are important considerations for thionamide treatment. New fever, significant sore throat, jaundice or dark urine may indicate serious drug toxicity and must not be left until a scheduled review.

Symptom relief versus definitive treatment

Beta blockers may reduce tachycardia, tremor, palpitations, and other adrenergic effects while hormone-directed treatment takes effect. They do not remove the excess hormone source. Assess bradycardia, asthma, hypotension, and other contraindications before use.

Radioactive iodine and surgery are possible definitive approaches, while iodide is used as an adjunct in selected settings. These options have distinct indications, reproductive implications, and follow-up needs. Some patients become hypothyroid after definitive therapy and require ongoing thyroid surveillance and possibly replacement hormone.

Matching treatments to clinical goals

Beta blockers relieve tremor, palpitations, and tachycardia but do not eliminate excess thyroid hormone production. Propranolol may be initiated at 10–40 mg four times daily as one example, titrated to symptomatic and heart-rate response when appropriate. Use requires assessment of asthma, decompensated HF, bradycardia, and other contraindications; a more selective beta blocker or alternate rate-control approach may be appropriate in selected patients.

Radioactive iodine is a definitive therapy for appropriate patients with hyperfunctioning tissue, while surgery may be preferred with large obstructive goiters, concern for malignancy, or other patient-specific factors. Iodide solutions are generally short-term adjuncts, such as before surgery or in thyroid storm, and are not interchangeable with chronic methimazole therapy. Patients should understand that definitive therapy frequently results in hypothyroidism requiring lifelong levothyroxine.

Different medications, different goals

A beta blocker addresses adrenergic symptoms such as palpitations or tremor but does not stop thyroid hormone synthesis. Thionamides reduce new hormone production; iodide may be used as an adjunct in selected perioperative or severe cases; radioactive iodine and surgery seek a more definitive reduction in thyroid function. When choosing among them, document etiology, severity, comorbidities, pregnancy considerations, expected duration, and the possibility of subsequent hypothyroidism.

Amiodarone-associated thyrotoxicosis requires mechanism-specific treatment

Amiodarone can alter thyroid tests through iodine exposure and peripheral hormone metabolism even in euthyroid patients. When true thyrotoxicosis occurs, type 1 is predominantly increased synthesis, often in a gland with underlying autonomy or Graves disease, whereas type 2 is destructive thyroiditis. A thionamide may be appropriate for synthesis-driven disease; destructive thyroiditis may require glucocorticoids under specialist direction. Mixed or uncertain presentations require integrated cardiac and endocrine assessment (Katz, 2026).

The choice to stop amiodarone is not a routine endocrine decision made in isolation: arrhythmia severity, drug persistence, cardiac alternatives, and the possibility of mixed mechanisms must be discussed with cardiology and endocrinology. Tachycardia may be less prominent because amiodarone itself has antiadrenergic effects, so symptom severity cannot be judged by pulse alone.

Adverse-effect recognition and urgent response

• Fever or a significant sore throat during methimazole or PTU therapy requires urgent assessment for agranulocytosis, with immediate clinical advice about withholding the medication and a CBC with differential. Jaundice, pruritus, dark urine, or right-upper-quadrant pain warrants prompt liver evaluation. Methimazole labeling additionally identifies vasculitis as a potentially serious adverse effect: a new rash with hematuria, reduced urine output, dyspnea, or hemoptysis warrants urgent assessment. Do not defer these evaluations until the next scheduled thyroid laboratory visit (Methimazole tablets, 2026; Katz, 2026).

• Jaundice, dark urine, severe systemic symptoms, or concerning abdominal pain require prompt evaluation for possible serious hepatic injury.

• Patients should understand signs of excessive versus inadequate thyroid treatment, the need for prescribed monitoring, and why abrupt self-directed regimen changes are unsafe.

• Medication reconciliation should include over-the-counter products and drugs affecting thyroid function or interacting with treatment.

Interpret laboratory response appropriately

Testing interference and illness can mimic disease

High-dose biotin can produce falsely high free T4 or falsely low TSH on susceptible immunoassay platforms, mimicking thyrotoxicosis without corresponding clinical findings. Reconcile supplements, illness, medications, and assay methodology before escalating treatment. For routine thyroid testing, the American Thyroid Association advises withholding biotin for 2 days; longer interruption may be needed with high doses or particular assays, so confirm the laboratory’s protocol. Do not initiate a thionamide solely to correct a suspected analytical artifact (American Thyroid Association, n.d.; Katz, 2026).

Use free hormone response when TSH remains suppressed early

During initial thionamide treatment of Graves disease, falling free T4 or T3 may demonstrate response before TSH recovers. Escalating methimazole solely because TSH is still suppressed may cause iatrogenic hypothyroidism. Once biochemically controlled, reassess maintenance dose and adverse effects. After approximately 12–24 months of treatment, discuss remission probability, TSH-receptor antibody trends where used, and a surveillance or definitive-therapy plan because relapse remains possible (Katz, 2026).

Document the biochemical target, planned laboratory date, adverse-symptom instructions, and intended duration of treatment. Fever or sore throat during thionamide exposure raises concern for agranulocytosis; jaundice, severe fatigue, or dark urine warrants urgent assessment for hepatic injury. Do not rely on routine scheduled testing alone to detect these uncommon but serious toxicities.

Pregnancy and special populations

Thyrotoxicosis during pregnancy is not automatically Graves disease. In early pregnancy, human chorionic gonadotropin can cause gestational transient thyrotoxicosis, often managed supportively without antithyroid medication. Confirm free T4 and assess Graves-specific features and TSH receptor antibodies when indicated before prescribing a thionamide. Patients with overt Graves hyperthyroidism need an individualized endocrine-obstetric plan balancing maternal disease control against fetal drug exposure. The 2026 ATA guidance supports PTU when treatment is required around conception and early gestation, but does not make a universal recommendation to switch everyone to methimazole after 16 weeks. Decisions about continuing, changing, or withdrawing therapy depend on disease activity, prior stability, thyroid laboratory results, hepatic risk, and fetal considerations (Korevaar et al., 2026).

Pediatric patients, patients with substantial cardiac disease, and those with significant Graves orbitopathy may require specialized treatment decisions. These situations warrant careful coordination and individualized treatment decisions.

Trimester-specific decisions

For Graves hyperthyroidism requiring antithyroid treatment in pregnancy, use the lowest effective dose and follow maternal TSH and free T4 closely, usually every two to four weeks during active treatment. PTU is generally favored during the period around conception and early pregnancy when medication is necessary, but the 2026 ATA guideline does not establish a universally preferred agent after 16 weeks; switching drugs can destabilize biochemical control. TRAb or TSI testing informs fetal risk, including the need for fetal surveillance when antibody levels are markedly elevated. Radioactive iodine remains contraindicated in pregnancy. Drug toxicity precautions, maternal symptoms, fetal well-being, and specialty follow-up must be addressed together (Korevaar et al., 2026).

Preconception counseling, breastfeeding, and postpartum relapse require explicit planning rather than a single rule that PTU is always safer in pregnancy. Pediatric hyperthyroidism also has different risk-benefit considerations and generally warrants pediatric endocrinology involvement.

Thyroid storm

Thyroid storm is a life-threatening form of thyrotoxicosis with systemic decompensation, such as fever, marked tachycardia, altered mental status, or organ dysfunction. It requires immediate hospital-based stabilization, treatment of precipitating illness, and coordinated antithyroid therapy (De Groot et al., 2025; Katz, 2026).

Emergency sequence and interdisciplinary care

Thyroid storm is a clinical emergency with severe adrenergic activation and multisystem dysfunction. Stabilize hemodynamics and treat the precipitant in monitored hospital care; pharmacologic management may include appropriately selected beta blockade, a thionamide to inhibit new hormone synthesis, iodide administered in the correct sequence after synthesis blockade, and glucocorticoids. Doses and contraindications depend on the active emergency protocol and the patient’s cardiac and hepatic status; outpatient Graves titration principles do not apply (Katz, 2026).

In thyroid storm attributed to excess hormone synthesis, give a thionamide before iodine; commonly used protocols administer potassium iodide at least 1 hour after the first antithyroid-drug dose to avoid providing additional substrate for hormone synthesis. This sequence is not a universal rule for every form of thyrotoxicosis, and iodide may be inappropriate in selected iodine-induced presentations. Treatment requires an institutional emergency pathway and endocrinology and critical-care involvement, not an extrapolation from outpatient instructions (De Groot et al., 2025; Katz, 2026).

Clinical application

Case: Fever and sore throat after starting methimazole

This is a possible severe drug reaction, not a routine nuisance symptom. The patient requires urgent assessment of thionamide toxicity and an immediate medication safety plan.

Case: Thyrotoxicosis associated with painful thyroiditis

Before starting a thionamide, determine whether the disorder reflects increased synthesis or release of preformed hormone. The mechanism determines whether synthesis inhibition is likely to help.

Case: Newly diagnosed Graves disease in pregnancy

Confirm gestational age, whether the abnormal thyroid tests reflect gestational transient thyrotoxicosis or Graves disease, biochemical severity, symptoms, prior antithyroid exposure, and TSH receptor antibody status when indicated. A first-trimester patient who is clinically stable with transient hCG-related biochemical changes may need monitoring rather than thionamide therapy; overt Graves disease may require prompt drug treatment with maternal and fetal surveillance. Document the endocrinology and obstetric follow-up arrangement and specific thyroid-test interval (Korevaar et al., 2026).

High-yield distinctions

Thyrotoxicosis is not synonymous with increased hormone synthesis. Distinguish antithyroid drug treatment, symptom relief, and definitive treatment, and reassess promptly if serious drug-related symptoms occur.

Related YourDNP Resources

Pharmacology hub · Hyperthyroidism · Hypothyroidism pharmacotherapy · Adrenal insufficiency pharmacotherapy · Diabetes monitoring

---

---

References

American Thyroid Association. (n.d.). Thyroid function tests. https://www.thyroid.org/thyroid-function-tests/

De Groot, L. J., Bartalena, L., & Feingold, K. R. (2025, April 15). Thyroid storm. In Endotext. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK278927/

Katz, M. D. (2026). Thyroid disorders. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 1420–1454). McGraw Hill.

Korevaar, T. I. M., Leung, A. M., Alexander, E. K., Bliddal, S., Boelaert, K., Brenta, G., Chou, R., Dhillon-Smith, R., Dosiou, C., Eaton, J. L., Guan, H., Kilpatrick, S. J., Lasserre, B. J., Lee, S. Y., Maraka, S., Meister, K. D., Morris-Wiseman, L. F., Nguyen, C. T., Pearce, E. N., & Shan, Z. (2026). American Thyroid Association 2026 guidelines for thyroid disease in preconception, pregnancy, and postpartum. Thyroid, 36(5), 481–544. https://doi.org/10.1177/10507256261445624

Methimazole tablets [Prescribing information]. (2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06bb4bcc-5e47-48b6-a76c-648f846704e8